EXPLORE THE FRONTIERS With Breakthrough Science!
Now that the public has a heightened awareness of the unfortunate side effects of traditional medications, the charge to deliver new solutions has brought novel treatments. As a result, once-maligned and over-regulated treatments are now offering the potential to change lives for the better.
Some of the most exciting developments are in the domain of mood disorders, such as depression and anxiety. As an alternative to older medications that tend to suppress the patient's personality, psychedelic medicine can actually enhance their personality. Oftentimes, the patient will report a highly positive and life-changing experience.
This is not the illegal 'drug trip' of street drugs, but a pathway to a 'better you' that we can all access. Psychedelic medicines derived from psilocybin and ketamine have the potential to help patients break down psychological walls and reconnect with themselves and those they care about.
In a time when shelter-in-place orders are disconnecting people from their family and friends, connections are more critical than ever. There's actually a phenomenon now known as 'pandemic anxiety,' where the population's mental health is reaching the breaking point because of the coronavirus.
How bad is it getting? One recent study of college students found that since the spread of the pandemic, 20% of college students are more depressed, 11% are more anxious, and 16% report being more lonely. When your circumstances are unpredictable and out of your control, these issues are bound to come to the surface.
Leading global institutions have taken the lead in researching psychedelic medicine, and their findings indicate that psilocybin-assisted therapy could be a revolutionary treatment for depression, anxiety, and even addiction to alcohol and tobacco. That's right: psychedelics are going mainstream, and Big Pharma will need to adapt to the changing scientific landscape.
The medical community is paying close attention, and so are investors and insiders who see what's coming down the pipeline. One of the most engaged companies today is Champignon Brands (CSE: SHRM, OTC: SHRMF), which specializes in identifying, commercializing and delivering psychedelic-based treatments.
CEO Roger McIntyre is a world-renowned expert in the use of psychedelics, such as psilocybin and ketamine, to treat depression and anxiety. Dr. McIntyre had the vision to implement and develop Canada's first-ever treatment center, the Canadian Rapid Treatment Centre of Excellence, to provide rapid-onset treatments for people with mood disorders.
Dr. McIntyre's accomplishments are numerous:
- He's published over 600 articles on the topic of mood disorders
- He authored an extensive number of books and chapters
- He's a top-ranked expert in the area of depression
- He's named one of the World's Most Influential Scientific Minds each year from 2014 to 2019 by Clarivate Analytics
Today, Champignon not only has the expertise of Dr. McIntyre, but also the only Health Canada-approved clinic to conduct randomized controlled trials for psilocybin and the largest depression-focused center of its type in the world. And since the Canadian Rapid Treatment Centre of Excellence is the leading Canadian ketamine clinic operator, Champignon is easily outpacing its peers in the areas of research and development.
Keep your eyes on Champignon Brands.
RECOMMENDATION: MAKE CHAMPIGNON BRANDS (CSE: SHRM, OTC: SHRMF) A CORE STOCK IN YOUR PORTFOLIO.
Consider becoming a shareholder of Champignon Brands (CSE: SHRM, OTC: SHRMF))
For further updates on Champignon Brands, subscribe now!